IGF-1 LR3

Long R3 IGF-1 · Long-acting IGF-1

Peptide peptide SubQ Published Clinical Data

Half-life

24 hr

Time to Peak

4 hr

Steady State

~5 days

Dose Range

20–100 mcg

Frequency

Daily

Overview

Modified analog of insulin-like growth factor 1 (IGF-1) with an arginine substitution at position 3 and a 13-amino acid N-terminal extension. These modifications reduce binding to IGF binding proteins (IGFBPs), dramatically extending the effective half-life to ~24 hours compared to ~15 minutes for native IGF-1. Used in bodybuilding and performance communities. Not approved for clinical use. Requires reconstitution with BAC water.

Mechanism of Action

Activates IGF-1 receptor (IGF-1R) to promote cell growth, proliferation, and differentiation. The LR3 modification reduces IGFBP sequestration, resulting in higher free IGF-1 activity and longer duration of action.

Dosing Information

Route Dose Range Half-life Tmax Frequency
Subcutaneous (SubQ) 20–100 mcg 24 hr 4 hr Daily

Storage & Handling

2-8C — Store lyophilized powder frozen or refrigerated. Reconstitute with BAC water. Handle carefully — IGF-1 peptides are sensitive to degradation.

Used in Regimens

IGF-1 LR3 is not currently part of any catalog regimen.

Data Sources

  • Peer-reviewed IGF-1 LR3 pharmacokinetics and IGFBP binding characteristics

Related Tools

Track IGF-1 LR3 with Doseline

Reminders, medication level charts, injection site rotation, and protocol tracking — all free, all private.

Join the waitlist

Doseline provides informational tools only. It is not a medical device and does not provide medical advice. Always consult a qualified healthcare provider.

Doseline provides informational tools only. It is not a medical device and does not provide medical advice. Always consult a qualified healthcare provider.